Molbio Diagnostics is set for a significant stock market debut following a robust IPO subscription of 70 times. With a promising grey market premium suggesting a 19.3% rise over its issue price, investors are eagerly awaiting Monday’s listing on the NSE and BSE.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.